Fair value · Rallybio Corp (RLYB) · updated 2026-10-29 · from 10-K FY2025
Rallybio trades at $15.99. That price implies a P/E of 5.2×, 10.0% yearly EPS growth for a decade and a 43.8% free-cash-flow yield.
Cboe · delayed 15 min · as of 20:05 ET
Are those assumptions reasonable? Use RLYB’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- P/E
- 5.2×
- EPS growth
- 10.0%
- FCF yield
- 43.8%
price ÷ trailing EPS
per year for 10 years, discounted at 10%
free cash flow ÷ enterprise value (2.3× EV/FCF)
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 20:05 ET.
Inputs come from the FY2025 10-K filed (accession 0001628280-26-018261); set your own on the sliders below. Research, not investment advice.
The filing behind these numbers
Rallybio Corp- Revenue
- $858000
- Diluted EPS
- $-1.59
- Free cash flow
- $-29.8M
- operating cash flow − capital expenditure
- Diluted shares
- 5.6M
- weighted average
10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-16 · accession 0001628280-26-018261
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q3 FY2026 (filed 2026-10-27).
Open this filing on sec.govNeed RLYB data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.